Home Drug Discovery and Development - Drug Discovery and Development

Today on Drug Discovery & Development

By Brian Buntz | July 1, 2022

U.S. purchases more monkeypox vaccine doses from Bavarian Nordic

Bavarian Nordic A/S (OMX:BAVA) has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 2.5 million doses of liquid-frozen Jynneos vaccine. FDA first approved Jynneos, a non-replicating smallpox and monkeypox vaccine, in 2019. It continues to be the only FDA-approved vaccine indicated for monkeypox. The company will begin deliveries…

By Brian Buntz | June 30, 2022

Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

Takeda (NYSE:TAK) has announced that in the open-label Phase 3 SPRING study, children aged 2 to 12 had 94.8% fewer hereditary angioedema (HAE) attacks during treatment with Takhzyro (lanadelumab-flyo) over 52 weeks compared to baseline. The Osaka, Japan–based company plans on presenting the data at the European Academy of Allergy and Clinical The SPRING study…

By Brian Buntz | June 30, 2022

Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer

Novartis (NYSE:NVS) has announced that chemotherapy plus tislelizumab, a humanized monoclonal antibody directed against PD-1, improved overall survival as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in the Phase 3 RATIONALE 306 study. The survival benefits were seen in patients regardless of PD-L1 status. The…

Read All Articles >

Drug Discovery and Development See More >

Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government

Pfizer Inc. (NYSE:PFE) and its partner BioNTech SE (Nasdaq:BNTX) profited handsomely from COVID-19 vaccine sales in 2021. The firms raked in more than $59 billion in combined sales of the Comirnaty vaccine. The two companies have now announced a new vaccine supply agreement with the U.S. government worth $3.2 billion. Under the terms of the…

Novartis to cut up to 8,000 positions

GSK to invest £1 billion on infectious disease research

CB Therapeutics hires new business development lead

2022 Pharma 50: The 50 largest pharmaceutical companies

Sponsored Content See More >

A new way to access scientific papers?

Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…

These are not fireworks: The objective truth

By Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…

AI technology automates tedious cell culture work and analyses

By Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…

What is Human AB Serum?

By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…

Resolving binding kinetics on a microplate reader

With a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…

Noble expands its services for its clients into Human Factors

Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…

Micro 3D Printing Advances Biomarker Detection

Researchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…

Genomics/Proteomics See More >

DNA Script raises $165M Series C for DNA printing platform

DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million. South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic…